



## argenx to Present at the 11th Annual SVB Leerink Global Healthcare Conference

**February 10, 2022**

**Breda, the Netherlands** – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the 11<sup>th</sup> Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 10:40 a.m. ET.

A live webcast of the presentation may be accessed on the Investors section of the argenx website at [argenx.com/investors](http://argenx.com/investors). A replay of the webcast will be available on the argenx website for approximately 90 days following the presentation.

### **About argenx**

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S. and Japan. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit [www.argenx.com](http://www.argenx.com) and follow us on [LinkedIn](#), [Twitter](#), and [Instagram](#).

### **For further information, please contact:**

#### **Media:**

Kelsey Kirk  
kkirk@argenx.com

Joke Comijn (EU)  
jcomijn@argenx.com

#### **Investors:**

Beth DelGiacco  
bdelgiacco@argenx.com

Michelle Greenblatt  
mgreenblatt@argenx.com